| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
153,922,000 |
| Market
Cap: |
6.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$39.95 - $39.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-11-13 |
2025-08-12 |
2025-02-11 |
2024-02-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gibney Anthony S |
EVP, Chief Business Officer |
• – – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(40,291) |
0 |
|
- |
|
| Westby Keith |
SVP, Chief Operating Officer |
• – – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(39,652) |
0 |
|
- |
|
| Carroll David Francis |
SVP, Chief Financial Officer |
• – – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(44,152) |
0 |
|
- |
|
| Bolte Axel |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,088) |
0 |
|
- |
|
| Simms Christopher Paul |
SVP, Chief Commercial Officer |
• – – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,429) |
0 |
|
- |
|
| Roberts Calvin W. |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(47,088) |
0 |
|
- |
|
| Henderson Jane |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,088) |
0 |
|
- |
|
| Dugel Pravin |
President |
• • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(203,035) |
0 |
|
- |
|
| Miller Christine Ann |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,075) |
0 |
|
- |
|
| Graves Adrienne L |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,088) |
0 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,088) |
0 |
|
- |
|
| Sblendorio Glenn |
Chief Executive Officer |
• • – |
2023-07-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(239,275) |
0 |
|
- |
|
| Westby Keith |
SVP, Chief Operating Officer |
• – – |
2023-07-03 |
4 |
AS |
$39.45 |
$789,000 |
D/D |
(20,000) |
39,652 |
|
1% |
|
| Westby Keith |
SVP, Chief Operating Officer |
• – – |
2023-07-03 |
4 |
OE |
$2.94 |
$58,800 |
D/D |
20,000 |
59,652 |
|
- |
|
| Gibney Anthony S |
EVP, Chief Business Officer |
• – – |
2023-06-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,500 |
40,291 |
|
- |
|
| Carroll David Francis |
SVP, Chief Financial Officer |
• – – |
2023-06-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
24,320 |
44,152 |
|
- |
|
| Sblendorio Glenn |
Chief Executive Officer |
• • – |
2023-06-22 |
4 |
OE |
$13.22 |
$146,486 |
D/D |
11,084 |
239,275 |
|
- |
|
| Westby Keith |
SVP, Chief Operating Officer |
• – – |
2023-06-02 |
4 |
AS |
$37.87 |
$757,400 |
D/D |
(20,000) |
39,652 |
|
5% |
|
| Westby Keith |
SVP, Chief Operating Officer |
• – – |
2023-06-02 |
4 |
OE |
$2.94 |
$58,800 |
D/D |
20,000 |
59,652 |
|
- |
|
| Graves Adrienne L |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,588 |
22,088 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,588 |
32,088 |
|
- |
|
| Henderson Jane |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,588 |
22,088 |
|
- |
|
| Roberts Calvin W. |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,588 |
47,088 |
|
- |
|
| Bolte Axel |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,588 |
22,088 |
|
- |
|
| Miller Christine Ann |
Director |
– • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,075 |
13,075 |
|
- |
|
300 Records found
|
|
Page 1 of 12 |
|
|
